Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > 100$ stock price

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Feb 15, 2021 4:57pm

167 Views

Post# 32569535

RE:RE:RE:RE:RE:RE:RE:RE:RE:100$ stock price

Marky1 wrote: As you said, it leads you to 15% dilution......That brings the total stock count to roughly 44.5 M shares. How do you account for the other 15.5 M shares to get to 60M.....Please educate me

Marky - page 31 of the presentation will guide you. You have shares, you have options and RSUs, you have warrants.

Then you have to think about other dilutions like future RSUs and options for the team.

-----

Hope that helps

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks